Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of BIIB122 in Healthy Japanese, Chinese, and Caucasian Adults
NCT05229562Phase 1Completed
- Sponsor
- Biogen
- Start
- Feb 2022
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of BIIB122 in Parkinson's disease (PD) (4 cohorts), sponsored by Biogen. Primary endpoints: Maximum Observed Plasma Concentration at Day 20, Time to Reach Maximum Observed Plasma Concentration at Day 20 and 4 more. Started Feb 2022; status: completed.
02
Drugs
BIIB122
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT05229562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05229562.